



## RESEARCH ARTICLE

## Thrombocytopenia as a Diagnostic Marker for Identifying Patients with Malaria in Endemic Regions

Niamatullah kakar<sup>1\*</sup>, Asmatullah<sup>2</sup>, Habib Ur-Rehman<sup>3</sup>, Zahid Mehmood<sup>4</sup>, Ashif sajjad<sup>5</sup>, Quadratullah<sup>6</sup>,  
Mohammad Ashraf<sup>7</sup>

Center for Advanced Studies in Vaccinology & Biotechnology (CASVAB), University of Baluchistan, Brewery road Quetta, Pakistan. \*Corresponding Author: Niamatullah kakar- Email: [niamatullah.kakar@gmail.com](mailto:niamatullah.kakar@gmail.com)

1. CASVAB, University of Balochistan, Quetta, Pakistan.
2. Faculty of pharmacy, University of Balochistan, Quetta, Pakistan.
3. CASVAB, University of Balochistan, Quetta, Pakistan.
4. Institute of Biochemistry, University of Balochistan, Quetta, Pakistan.
5. Institute of Biochemistry, University of Balochistan, Quetta, Pakistan.
6. Agriculture University Faisalabad, Pakistan.
7. Fatima Jinnah General & Chest Hospital Quetta, Pakistan.

### Manuscript Info

#### Manuscript History:

Received: 15 February 2014  
Final Accepted: 20 March 2014  
Published Online: April 2014

#### Key words:

Malaria, Thrombocytopenia,  
*Plasmodium falciparum*, *P. vivax*,  
Anemia Endemic

#### \*Corresponding Author

Niamatullah kakar

### Abstract

Malaria can present in a myriad of hematological alterations with thrombocytopenia being one of those. It is typically diagnose by the microscopic examination of the blood using blood film. The aim of the present study was to screen all patients with thrombocytopenia for the prevalence of malaria during the seasonal malaria. The patients with thrombocytopenia were included in the study. A total of 389 cases having thrombocytopenia were identified; malaria was seen in 21.8%. Among the conformed malarial patients, 63.5% *Plasmodium falciparum* and 36.5% *Plasmodium vivax* was seen. Further it was observed that 91.7% of thrombocytopenic patients with malaria were also had some degree of anemia as well. Taken together, a total of 20 patients had pancytopenia with more 41.9% cases with *P. vivax* and 13% with *P. falciparum*. Based on our findings, we advocate the use of thrombocytopenia as an important marker in the diagnosis of malaria; and in endemic regions patients with thrombocytopenia should be screened for possible malaria.

Copy Right, IJAR, 2014., All rights reserved.

### Introduction:

Malaria is a life-threatening disease caused by parasites of genus plasmodium that are transmitted by Malaria vectors to man through the bites of infected female Anopheline mosquitoes. There are five plasmodium species (*Plasmodium falciparum*, *Plasmodium vivax*, *Plasmodium malariae*, *plasmodium ovale* and *Plasmodium knowlesi*) causes human malaria, among which the *P. falciparum* and *P. vivax* are the most common and *P. falciparum* is the most deadly.

According to world health organization (WHO) report in 2013 it is estimated about 207 million cases of malaria in 2012 and accounts for an estimated 627000 deaths. (WHO, 2013) A vast majority, about 85% malarial cases were in

African Region, followed by the South-East Asian Region (10%) and 4% from East Mediterranean region. 89% of the death cases reported from African Region followed by East Mediterranean (6%) and 5 % from South-East Asia Region (Gupta et al., 2013).

Malaria parasite affects multiple human organs such as brain spleen, liver gastrointestinal tract (GIT), Gall bladder and blood vessels. Therefore the clinical picture may be of wide range that is from simple malaise to life threatening central nervous expression like coma. Blood abnormalities have been observed in patients with malaria; Anemia and thrombocytopenia is the most common (Wickramasinghe, 2000; Khan, 2008).

The frequency and severity of thrombocytopenia appears to vary with the severity of infection and the type of malarial parasites (Leowattana et al., 2010; Kochar et al., 2010). Thrombocytopenia could also be a marker for the presence of malaria in endemic regions (Maina et al., 2010). 961 children from Kenya, children with low platelet counts ( $<150,000/\text{mm}^3$ ) were 13.8 times more likely to have malaria. Similarly in a systematic review on returning travelers to endemic regions, thrombocytopenia had a likelihood ratio of 5:6 (confidence interval 4.1-7.5) of predicting malaria (Taylor et al., 2010).

It has therefore, been suggested by several authors that it may be cost effective for patients with low platelet counts in malaria endemic regions to be systematically screened for the presence of malarial parasites (Mbanya et al., 2002). This is further corroborated by our literature review as outlined in Table 1 where thrombocytopenia was noted ranging from a quarter to all patients with Malaria; along with severe thrombocytopenia ( $< 50,000 /\text{mm}^3$ ) being present in up to half of the patients. Our aim, therefore, was to screen all patients with thrombocytopenia presenting to lab for the presence of malaria during the malaria season and thus evaluate the efficacy of routine testing for malaria in patients presenting with thrombocytopenia.

## Materials and Methods:

Ethical approval for the study was obtained from Provincial Reference laboratory (PRL) Malaria control program, Fatima Jinnah General & Chest Hospital Quetta and the research conducted was performed according to the Declaration of Helsinki.

The study was a prospective carried out at PRL Malaria control program Fatima Jinnah General & chest Hospital, tertiary care hospital in the city of Quetta, Baluchistan, the largest province in Pakistan. Quetta is a metropolitan city and the capital of the province. People belonging to different communities live here along with many refugees from the country Afghanistan migrated during the early 1980s and 1990s. With respect to Malaria, according to WHO EMRO, the estimated number of annual malaria episodes in Pakistan is 1.5 million; among which 40% were reported from province Baluchistan (WHO, 2011).

Automated complete blood counter was used to detect thrombocytopenia and all the positive patients were included in the study. Further, the presence of thrombocytopenia was confirmed manually; and thick and thin Giemsa smears were also prepared and evaluated for the presence of malarial parasites. Data on other hematological parameters was also recorded. A database was built in Microsoft Access for input of the data.

## Results:

Among the studied a total of 389 cases were identified as having thrombocytopenia (Platelet count  $< 150,000/\text{mm}^3$ ). Out of identified cases 85 (21.85%) cases and further their smears were found to be positive for Malaria; i.e. nearly 1 in every 5 patient with thrombocytopenia had underlying malaria. 63.5% cases were found positive for *P. falciparum* and 36.5% cases also for *P. vivax* infection.

**Table I: Research Articles documenting the incidence of Thrombocytopenia in patients with malaria<sup>†</sup>**

S.NO	PAPER [REFERENCES]	TYPE OF MALARIAL PARASITES	THROMBOCYTOPENIA [NO OF CASES]	%age	SEVERE THROMBOCYTOPENIA [NO OF CASES]	%age
1.	Singh et al 2011 (25)	<i>P. vivax</i>	22	96	9 (< 50,000)	36
2.	Kochar et al (6)	All types	262	24.6		
		<i>P. vivax</i>	143	31.09	26 (< 20,000)	18.18
		<i>P. falciparum</i>	85	16.19	9 (< 20,000)	10.59
3.	Sharma et al (26)	<i>P. vivax</i>	213	96.3	13 (< 20,000)	6.1
4.	Ansari et al (27)	<i>P. falciparum</i>	256	69.18	180 (<50,000) 37 (<20,000)	48.6 10
5.	Rodriguez et al (28)	<i>P. vivax</i>	46	58.97	18 (<60,000)	24.36
6.	Jadhav (29)	Both types	1242	79.4		
		<i>P. falciparum</i> <i>P. vivax</i>			50 (<20,000) 15 (<20,000)	8.5 1.5
7.	Rasheed et al (30)	Mixed	248	80		
8.	Maina et al 2010 (7)	<i>P. falciparum</i>	256	49		
9.	De Laval et al 2010 (31)	<i>P. Ovale</i>	31	50		
10.	Leowattana et al (5)	Uncomplicated and Complicated <i>P. falciparum</i>	81	73.6		
			100	90.9		
11.	Inan et al (32)	Both <i>P. falciparum</i> and <i>P. vivax</i>	15	75		
12.	Malik et al (33)	Both <i>P. falciparum</i> and <i>P. vivax</i>	274	70		
13.	Parakh et al (34)	Severe <i>P. vivax</i> Malaria	5	100		
14.	Shaikh et al (35)	Both types	100	80.6		
		<i>P. falciparum</i>	46	71.87		
		<i>P. vivax</i>	56	93.33		
15.	Daneshvar et al (36)	<i>P. Knowlesi</i>	107	100		
16.	Taylor et al (37)	Both <i>P. falciparum</i> and <i>P. vivax</i>	119	78.8		
17.	Lee et al (24)	<i>P. vivax</i>	185	95.4		
18.	Adedapo et al (38)	<i>P. falciparum</i>	412	59.3		
19.	Obaldia et al (39)	<i>P. vivax</i>	20 (an animal study)	77		
20.	Beg et al (40)	Mainly <i>P. falciparum</i> and <i>P. vivax</i>	189	36.4		
21.	Kumar et al (21)	<i>P. vivax</i>	24	88.9		

<sup>†</sup> Please note that 2 articles in pubmed by Mbanya et al and Inan et al were not in English; incidence was noted from the abstract in English

**Table II: Frequency of severity of thrombocytopenia based on Malarial subtype**

S.No	Thrombocytopenia	<i>P. falciparum</i> No of cases	Percentage	<i>P. vivax</i> No of cases	Percentage
1.	Mild (100,000 – 150,000 /mm <sup>3</sup> )	21	38.9%	14	45.2%
2.	Moderate (50,000-99,000)	18	33.3%	08	25.8%
3.	Severe (20,000-49,000 /mm <sup>3</sup> )	10	18.5%	08	25.8%
4.	Very severe (10,000-19,000 / mm <sup>3</sup> )	05	9.3%	01	3.2%
	Total	54		31	

**Table III: Frequency of changes in WBC count and severity of anemia based on malarial subtype**

VARIABLE	<i>P. falciparum</i>		<i>P. vivax</i>	
	No	% age	No	% age
<b>WBC COUNT</b>				
Normal WBC Count	47	87	18	58
Leucopenia	7	13	11	35.5
Leukocytosis	0	0	2	6.5
Total	54		31	
<b>SEVERITY OF ANEMIA</b>				
Normal	3	5.6	3	9.7
Mild (10-13.8 g/dl for males and 10-12.1 g/dl for females)	28	51.8	14	45.2
Moderate (8-9.9 g/dl)	15	27.8	8	25.8
Severe (< 8 g/dl)	8	14.8	6	19.3
Total	54		31	
<b>PANCYTOPENIA</b>				
Pancytopenia	7	13	13	41.9

## Discussion:

Based on literature search, the degree of thrombocytopenia has been classified into various groups; with severe being defined as  $< 50,000 / \text{mm}^3$  (Gupta et al., 2013). We classified thrombocytopenia into four groups as outlined in Table II. There were 41.2% cases mild thrombocytopenia, 30.6% moderate thrombocytopenia, 21.2% severe thrombocytopenia and 7% very severe degree of thrombocytopenia.

Based on literature search thrombocytopenia is commonly associated with *P. falciparum* and has been also reported to occur in patients co infected with *P. falciparum* and *P. vivax*. Its occurrence has less commonly reported in cases of *P. vivax* malaria (Morales et al., 2005). Table II outlines the severity of thrombocytopenia based on *P. falciparum* and *P. vivax*. Based on the definition of severe thrombocytopenia ( $< 50,000 / \text{mm}^3$ ) used by several authors Table 1, a total of 28.2% cases had severe degree of thrombocytopenia. Most of the cases in our study were caused by *P. falciparum*, along with it being the etiology in the very severe cases as mentioned in Table II. The mean of Mean Platelet Volume (MPV; normal 6-13 fl) was observed to be 7.83 fl (range 3.1-11.9fl). In a study of McKenzie et al, (2005) demonstrated the effect of malaria on a total leucocytes counts and found leucopenia in the *P. falciparum* infected patients than those in the *P. vivax*, which, in turn, were lower than those in the uninfected patients. In our study 21.2% patients found with leucopenia, 2.4% of the patients were with increased leucocytes count and 76.4% of the patients were with a normal White Blood Cell (WBC) count. Decrease in hemoglobin (Hb) concentration leading to anemia is frequently associated with malaria infection. Among the parasites species *P. falciparum* causes the most deadly and profound anemia with high risk of death (Menendez et al., 2000). In our research work we found about 91.7% of thrombocytopenic patients with positive malaria were also had some degree of anemia as well. Among them 49.4% cases had degree of anemia, 27.1% had moderate degree of anemia and 16.5% had severe degree of anemia. Taken together, a total of 20 patients had pancytopenia 41.9% patients with *P. vivax* and 13% patients with *P. falciparum*. Likewise in a study on pancytopenia in children, malaria was the cause in 8.69% of the cases (Memon et al., 2008). Although, both *P.*

*falciparum* and *P. vivax* have been reported in literature to cause pancytopenia, it is more often seen in association with *P. falciparum*. In our study, more cases of pancytopenia were noted within patients with *P. vivax* infection.

Although thrombocytopenia is a hematological disorder and develop early on in malarial patients, however the exact mechanisms behind its pathogenesis are not completely understood (De Mast et al., 2010). According to the findings of Coelho et al, (2013) indicated that platelet phagocytosis may contribute to thrombocytopenia found in vivax malaria. Identification of thrombocytopenia is important not only as a screening tool for identification of malaria in endemic regions but also has important prognostic significance. In a study from Zambia, thrombocytopenia had the strongest association with the presence of cerebral malaria (Thuma et al., 2011). Apparently, platelet activation by plasmodium can potentially lead to the formation of micro-aggregates of infected red blood cells and platelets which can occlude blood vessels and it also leads to binding to and activation of the endothelium (Cox et al., 2010). Increased Von Willebrand Factor concentrations along with decreased ADAMTS13 activity is also thought to play a role; along with oxidative stress, alterations in splenic function and immune mechanisms (Löwenberg et al., 2010; de Mast et al., 2009; Kumar et al., 2006).

Thrombocytopenia is not only seen as a feature of severe disease but also is frequently seen in asymptomatic cases of malaria in endemic regions and travelers bringing 'imported malaria (Jeremiah et al., 2007; Chung et al., 2007). Based on our findings, we strongly advocate the use of thrombocytopenia as an important aid in the diagnosis of malaria; especially in areas within developing countries where hematologists may not be as readily available to diagnose malaria based on thick and thin smears. Scoring systems may be developed which could incorporate common signs and symptoms like fever, hepato-splenomegaly and thrombocytopenia and/or anemia; since the results of an automated complete blood count are readily available even in remote facilities. The usefulness of thrombocytopenia in helping aid the diagnosis is elucidated well by an interesting study by Lee et al, (2008) examined the sensitivity and specificity of a malarial antigen test in an area where *P. vivax* was endemic. Alone, the sensitivity and specificity of the antigen test for malaria was 96.4% and 98.9% respectively. When thrombocytopenia was added to the evaluation, the positive predictive value of the test rose to 100%; thereby aiding in the diagnosis.

Thrombocytopenia is therefore, not only an important diagnostic and prognostic marker of severe malarial illness in endemic regions; but also can aid in the diagnosis in travelers to regions where malaria is an epidemic. Scoring systems incorporating the use of thrombocytopenia should be developed.

### **Conclusions:**

Based on our findings, we advocate the use of thrombocytopenia as an important aid in the diagnosis of malaria; and in endemic regions patients with thrombocytopenia should be screened for possible malaria. Scoring systems incorporating the use of thrombocytopenia should be developed. Table 1 summarizes the frequency of thrombocytopenia noted in different studies on thrombocytopenia and malaria; and reiterates the importance of screening these patients for presence of underlying malaria.

### **Acknowledgements:**

We are deeply indebted to the Pathology department, Fatima Jinnah General & Chest Hospital Quetta for their constant support and encouragement and the technical staff of the laboratory for assistance in carrying out the study. We are also very grateful to the hard work put in by Mujeeb ur Rehman and Jameel ur Rehman for helping in putting together the initial database.

### **Declaration of interest:**

All authors declared that they have no conflict of interest.

### **References:**

1. Adedapo AD, Falade CO, Kotila RT, Ademowo GO. (2007). Age as a risk factor for thrombocytopenia and anaemia in children treated for acute uncomplicated falciparum malaria. J Vector Borne Dis. 4: 266-71.
2. Ansari S, Koharo HK, Abro A, Akhund IA, Qureshi F. (2009). Thrombocytopenia in *P. falciparum* malaria. J Ayub Med Coll Abbottabad. 2: 145-7.

3. Beg MA, Sani N, Mehraj V, Jafri W, Khan MA, Malik A, Menezes E, Hussain R, Smego R Jr. (2008). Comparative features and outcomes of malaria at a tertiary care hospital in Karachi, Pakistan. *Int J Infect Dis*. 1: 37-42.
4. Chung HC, Wang JT, Sun HY, Wang JL, Lo YC, Sheng WH, Hsieh SM, Fang CT, Hsueh PR, Chen YC, Chang SC. (2007). Clinical experience of 17 cases of imported malaria at a Taiwan university hospital 1999-2005. *J Microbiol Immunol Infect*. 3: 209-15.
5. Coelho HCC, Lopes SCP, Pimentel JPD, Nogueira PA, Costa FTM, Siqueira AM, Melo GC, Monteiro WM, Malheiro A, Lacerda MVG. (2013). Thrombocytopenia in *P. vivax* Malaria Is related to Platelets Phagocytosis. *PLOS ONE*. 8: e63410.
6. Cox D, McConkey S. (2010). The role of platelets in the pathogenesis of cerebral malaria. *Cell Mol Life Sci*. 4: 557-68.
7. Daneshvar C, Davis TM, Cox-Singh J, Rafa'ee MZ, Zakaria SK, Divis PC, Singh B. (2009). Clinical and laboratory features of human *Plasmodium knowlesi* infection. *Clin Infect Dis*. 6: 852-60.
8. de Laval F, Oliver M, Rapp C, Pommier de Santi V, Mendibil A, Deparis X, Simon F. (2010). The challenge of diagnosing *P. ovale* malaria in travellers: report of six clustered cases in French soldiers returning from West Africa. *Malar J*. 9: 358.
9. De Mast Q, de Groot PG, van Heerde WL, Roestenberg M, van Velzen JF, Verbruggen B, Roest M, McCall M, Nieman AE, Westendorp J, Syafruddin D, Fijnheer R, van Dongen-Lases EC, Sauerwein RW, van der Ven AJ. (2010). Thrombocytopenia in early malaria is associated with GPIb shedding in absence of systemic platelet activation and consumptive coagulopathy. *Br J Haematol*. 151: 495-503.
10. de Mast Q, Groot E, Asih PB, Syafruddin D, Oosting M, Sebastian S, Ferwerda B, Netea MG, de Groot PG, van der Ven AJ, Fijnheer R. (2009). Deficiency with elevated levels of ultra-large and active von Willebrand factor in *P. falciparum* and *P. vivax* malaria. *Am J Trop Med Hyg*. 3: 492-8.
11. Gupta NK, Bansal SB, Jain UC, Sahare K. (2013). Study of thrombocytopenia in patients of malaria. *Trop Parasitol*. 1: 58-61.
12. Inan AS, Erdem I, Engin DO, Hitit G, Ceran N, Senbayrak S, Ozyürek SC, Karagül E, Göktaş P. (2010). Malaria: an evaluation of 40 cases. *Turkiye Parazitoloj Derg*. 3: 147-51.
13. Jadhav UM, Patkar VS, Kadam NN. (2004). Thrombocytopenia in malaria--correlation with type and severity of malaria. *J Assoc Physicians India*. 52: 615-8.
14. Jeremiah ZA, Uko EK. (2007). Depression of platelet counts in apparently healthy children with Asymptomatic malaria infection in a Nigerian metropolitan city. *Platelets*. 6: 469-71.
15. Khan SJ, Khan FR, Usman M, Zahid S. (2000). Malaria can lead to thrombocytopenia. *Rawal Med J*. 33:183-5.
16. Kochar DK, Das A, Kochar A, Middha S, Acharya J, Tanwar GS, Gupta A, Pakalapati D, Garg S, Saxena V, Subudhi AK, Boopathi PA, Sirohi P, Kochar SK. (2010). Thrombocytopenia in *Plasmodium falciparum*, *P. vivax* and mixed infection malaria: a study from Bikaner (Northwestern India). *Platelets*. 8: 623 -7
17. Kumar A, Shashirekha. (2006). Thrombocytopenia--an indicator of acute vivax malaria. *Indian J Pathol Microbiol*. 4: 505-8.
18. Lee SW, Jeon K, Jeon BR, Park I. (2008). Rapid diagnosis of vivax malaria by the SD Bioline Malaria Antigen test when thrombocytopenia is present. *J Clin Microbiol*. 3: 939-42.



19. Leowattana W, Tangpukdee N, Thar SK, Nakasiri S, Srivilairit S, Kano S, Wilairatana P, Krudsood S. (2010). Changes in platelet count in uncomplicated and severe falciparum malaria. *Southeast Asian J Trop Med public Health*. 5:1035-41.
20. Löwenberg EC, Charunwatthana P, Cohen S, van den Born BJ, Meijers JC, Yunus EB, Hassan MU, Hoque G, Maude RJ, Nuchsongsin F, Levi M, Dondorp AM. (2010). Severe malaria is associated with a deficiency of von Willebrand factor cleaving protease. *ThrombHaemost*. 1: 181-7.
21. Maina RN, Walsh D, Gaddy C, Hongo G, Waitumbi J, Otieno L, Jones D, Ogutu BR. (2010). Impact of *P. falciparum* infection on haematological parameters in children living in Western Kenya. *Malar J*. 3: 9.
22. Malik AM, Zaffar N, Ali N, Malik AM, Khan R. (2010). Haematological findings and endemicity of malaria in Gadap region. *J Coll Physicians Surg Pak*. 2: 112-6.
23. Mbanya D, Tapko JB, Azowe F, Kaptue L. (2002). Aetiologic factors and clinical features associated with thrombocytopenia in Cameroonian adults: the importance of *P. falciparum* malaria. *Sante*. 3: 331-5.
24. McKenzie FE, Prudhomme WA, Magill AJ, Forney JR, Permpnich B, Lucas C, Gasse RA, Wongsrichanalai C. (2005). White Blood Cell Counts and Malaria. *Journal of Infect Disease*. 192: 323–330.
25. Memon S, Shaikh S, Nizamani MA. (2008). Etiological spectrum of pancytopenia based on bone marrow examination in children. *J Coll Physicians Surg Pak*. 18: 163-7.
26. Menendez C, Fleming AF, Alonso PL. (2000). Malaria-related anaemia. *Parasitol Today*. 16: 469-76.
27. Morales AJR, Vargas EM, Piccolo C, Colina R, Arria M, Franco-Paredes C. (2005). Occurrence of Thrombocytopenia in *P. vivax* Malaria. *Clinical Infectious Diseases*. 41:129-30.
28. Obaldía N. (2007). Clinico-pathological observations on the pathogenesis of severe thrombocytopenia and anemia induced by *P. vivax* infections during antimalarial drug efficacy trials in Aotus monkeys. *Am J Trop Med Hyg*. 1: 3-13.
29. Parakh A, Agarwal N, Aggarwal A, Aneja A. (2009). *P. vivax* malaria in children: uncommon manifestations. *Ann Trop Paediatr*. 4: 253-6.
30. Rasheed A, Saeed S, Khan SA. (2009). Clinical and laboratory findings in acute malaria caused by various plasmodium species. *J Pak Med Assoc*. 4: 220-3.
31. Rodríguez-Morales AJ, Sánchez E, Vargas M, Piccolo C, Colina R, Arria M. (2006). Anemia and thrombocytopenia in children with *P. vivax* malaria. *J Trop Pediatr*. 1: 49-51.
32. Shaikh QH, Ahmad SM, Abbasi A, Malik SA, Sahito AA, Munir SM. (2009). Thrombocytopenia in malaria. *J Coll Physicians Surg Pak*. 11: 708-10.
33. Sharma A, Khanduri U. (2009). How benign is benign tertian malaria? *J Vector Borne Dis*. 2: 141 - 4.
34. Singh H, Parakh A, Basu S, Rath B. (2011). *P. vivax* malaria: Is it actually benign? *J Infect Public Health*. 2: 91-5.
35. Taylor SM, Molyneux ME, Simel DL, Meshnick SR, Juliano JJ. (2010). Does this patient have malaria? *JAMA*. 18: 2048-56
36. Taylor WR, Widjaja H, Basri H, Ohrt C, Taufik T, Tjitra E, Baso S, Fryauff D, Hoffman SL, Richie TL. (2008). Changes in the total leukocyte and platelet counts in Papuan and non Papuan adults from northeast Papua infected with acute *P. vivax* or uncomplicated *P. falciparum* malaria. *Malar J*. 7: 259.
37. Thuma PE, van Dijk J, Bucala R, Debebe Z, Nekhai S, Kuddo T, Nourai M, Weiss G, Gordeuk VR. (2011).

Distinct clinical and immunologic profiles in severe malarial anemia and cerebral malaria in Zambia. *J Infect Dis.* 2: 211-9.

38. Wickramasinghe SN, Abdullah SH. (2000). Blood and bone marrow changes in malaria. *Baillieres Best Pract Res Clin Haematol.* 13:277-99.

39. World Health Organization. World Malaria report 2013. Downloaded from <http://www.who.int/mediacentre/factsheets/fs094/en/>.

40. World Health organization. EMRO Website on Malaria in Pakistan. (2011). Downloaded from: - pak.htm; June.